Study guide

6.8 Biological Exposure Indices (BEIs) and Biomonitoring

CIH Certified Industrial Hygienist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The CIH Exam and How to Use This Guide

1.1 CIH Exam Format, Scoring, and Test-Day Logistics 1.2 Eligibility, Application Windows, Fees, and Certification Maintenance 1.3 The BGC Blueprint, Subject Areas, and a Calculation-First Study Plan

2 Chapter 2: Basic Science & Calculations

2.1 Gas Laws and Vapor Calculations 2.2 Unit Conversions: ppm, mg/m³, and Standard Temperature/Pressure 2.3 Fluid Mechanics and Airflow Fundamentals

3 Chapter 3: Air Sampling & Instrumentation

3.1 Active and Passive Air Sampling Strategies 3.2 Particulate and Aerosol Sampling 3.3 Direct-Reading Instruments and Calibration

4 Chapter 4: Analytical Chemistry & Lab Methods

4.1 Gas Chromatography and Mass Spectrometry 4.2 High-Performance Liquid Chromatography and Ion Chromatography 4.3 Spectroscopy and Elemental Analysis 4.4 Gravimetric, Microscopy, and Wet Chemical Methods 4.5 Laboratory Quality Assurance, Chain of Custody, and Desorption Efficiency

5 Chapter 5: Biostatistics & Epidemiology

5.1 Lognormal Distributions and Exposure Data Statistics 5.2 Upper Confidence Limits (UCL95) and Compliance Decision Rules 5.3 Epidemiological Study Designs and Measures of Association 5.4 Sampling Strategy: Sample Size, Power, and Worker Selection

6 Chapter 6: Toxicology & Biological Monitoring

6.1 Dose-Response Relationships and Points of Departure 6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination 6.3 Aerosol Deposition, Clearance, and Respiratory Tract Dosimetry 6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity 6.5 Pulmonary Toxicology, Carcinogenicity, and Reproductive Hazards 6.6 OEL Frameworks, Classifications, and Excursion Limits 6.7 Chemical Mixtures and Extended Work-Shift OEL Adjustments 6.8 Biological Exposure Indices (BEIs) and Biomonitoring

7 Chapter 7: Biohazards & Indoor Environmental Quality

7.1 Mold, Fungi, and Microbial Contaminants 7.2 Infectious Agents, Bloodborne Pathogens, and Biosafety Levels 7.3 Indoor Environmental Quality (IEQ) Investigations 7.4 Sanitation, Potable Water, and Personal Hygiene Programs

8 Chapter 8: Community Exposure & Environmental Health

8.1 Clean Air Act Framework, NAAQS, and New Source Review 8.2 Hazardous Air Pollutants, CEMS, and EPA Reference Methods 8.3 Atmospheric Stability, Lapse Rates, and Plume Morphology 8.4 Gaussian Plume Modeling, Plume Rise, and Environmental Fate 8.5 HAZWOPER Scope, Mandates, and Training Tiers 8.6 Protection Levels, Site Zoning, Incident Command, and Decontamination 8.7 Water Pollution, Hazardous Waste, and Community Right-to-Know

9 Chapter 9: Health Risk Analysis & Hazard Communication

9.1 GHS Hazard Classification: Health and Physical Hazard Criteria 9.2 GHS Labels, Safety Data Sheets, and Trade Secret Rules 9.3 The AIHA Exposure Assessment Strategy and Similar Exposure Groups 9.4 Qualitative Exposure Profiling and the AIHA Risk Matrix 9.5 Quantitative Health Risk Characterization: HQ, HI, and ELCR 9.6 NIOSH Occupational Exposure Banding 9.7 Risk Communication and Reporting to Affected Parties

10 Chapter 10: Industrial Ventilation Principles & LEV Design

10.1 Elimination, Substitution, Isolation, Containment, and Process Change 10.2 LEV Hood Taxonomy and Capture Velocity Selection 10.3 Hood Airflow Equations, Entry Losses, and Hood Static Pressure 10.4 Particulate Transport Aerodynamics and Duct Sizing 10.5 Duct Friction, Fitting Losses, and System Balancing 10.6 Fan Categories and Pressure Dynamics Across the Fan 10.7 System Curves, the Fan Laws, and Density Corrections

11 Chapter 11: General Ventilation, Air Cleaning & Diagnostics

11.1 Dilution Ventilation Principles and Steady-State Modeling 11.2 Transient Purging and Air Distribution Geometry 11.3 Particulate Air Cleaning: Cyclones, Baghouses, Scrubbers, and ESPs 11.4 Gaseous Emission Control and Air Cleaner Selection 11.5 Ventilation System Troubleshooting and Testing

12 Chapter 12: Noise Measurement & Hearing Conservation

12.1 Acoustic Physics and Decibel Mathematics 12.2 Sound Propagation, Octave Bands, and Frequency Weighting 12.3 Noise Dose Metrics and OSHA versus ACGIH Criteria 12.4 Exchange Rates, Extended Shifts, and Dosimetry Field Protocols 12.5 Engineering Noise Controls and Hearing Protector Attenuation 12.6 Hearing Conservation Programs and Standard Threshold Shifts 12.7 Hand-Arm and Whole-Body Vibration

13 Chapter 13: Thermal Stress Assessment & Control

13.1 Wet Bulb Globe Temperature (WBGT) and Heat Stress Indices 13.2 Heat-Related Disorders, Acclimatization, and Work/Rest Regimens 13.3 Cold Stress Evaluation and Wind Chill

14 Chapter 14: Ionizing Radiation Protection

14.1 Ionizing Radiation Physics and Radioactive Decay Kinetics 14.2 Radiation Units, Radiobiology, and Health Effects 14.3 ALARA, Stay-Time, and the Inverse Square Law 14.4 Shielding Physics, Material Selection, and Gamma Constants 14.5 Radiation Detection Instruments and Spectrometry 14.6 Personnel Dosimetry, Dose Limits, and Contamination Surveys

15 Chapter 15: Non-Ionizing Radiation & Laser Safety

15.1 The Non-Ionizing Spectrum and Static/ELF Field Exposures 15.2 Radiofrequency and Microwave Exposure: SAR, Standards, and Surveys 15.3 Ultraviolet, Visible, and Infrared Radiation Hazards 15.4 Laser Safety Classifications and Optical Density Calculations 15.5 Illumination, Lighting Design, and Visual Performance

16 Chapter 16: Non-Engineering Controls & Personal Protective Equipment

16.1 Respiratory Protection Programs and Assigned Protection Factors 16.2 Maximum Use Concentration, Oxygen Deficiency, and Breathing Air 16.3 Particulate Filters, Sorbent Cartridges, and Change Schedules 16.4 Respirator Fit Testing Protocols 16.5 Chemical Protective Clothing and Dermal Exposure Control

17 Chapter 17: Ergonomics & Workstation Design

17.1 Soft-Tissue Biomechanics and WMSD Pathophysiology 17.2 Ergonomic Risk Factors and Their Interaction Effects 17.3 The Revised NIOSH Lifting Equation 17.4 RULA, REBA, the Strain Index, and the ACGIH HAL TLV 17.5 Anthropometry and Workstation Geometry 17.6 VDT Workstations, Hand Tool Design, and Administrative Ergonomics

18 Chapter 18: Work Environments & Industrial Processes

18.1 Welding Fume Emissions, Metal Fume Fever, and Cr(VI)/Manganese Toxicology 18.2 Foundry Operations and Hot Work Fire Prevention 18.3 Vapor Degreasing, Pickling, Electroplating, and Cyanide Baths 18.4 Spray Coatings, Isocyanates, and Semiconductor Manufacturing 18.5 Confined Spaces and High-Hazard Industrial Operations 18.6 Asbestos, Lead, and Silica: Regulated Substance Programs 18.7 Abrasive Blasting and Surface Preparation

19 Chapter 19: IH Program Management & Professional Ethics

19.1 The BGC Code of Ethics: Canons and Enforcement 19.2 Professional Liability, Standard of Care, and Expert Testimony 19.3 Occupational Health & Safety Management Systems (ISO 45001, ANSI Z10) 19.4 Exposure Records Access and Medical Surveillance 19.5 OSHA Injury and Illness Recordkeeping and Enforcement

6.8 Biological Exposure Indices (BEIs) and Biomonitoring

Key Takeaways Explain This Topic AI

ACGIH Biological Exposure Indices (BEIs) represent determinant levels in biological specimens (blood, urine, exhaled breath) that correspond to internal doses absorbed by healthy workers exposed at the airborne TLV.

Specimen collection timing must align strictly with toxicokinetics: Prior to shift (slowly eliminated compounds), End of shift (rapid metabolites with t1/2 < 5 hr), End of workweek (accumulating agents with t1/2 15-40 hr), or Discretionary (stable lifetime markers).

Occupational lead biomonitoring relies on whole blood lead level (BLL); OSHA mandates medical removal at BLL >= 50 ug/dL (General Industry average/single 60 ug/dL) with return at < 40 ug/dL, whereas modern ACGIH guidelines set a BEI of 20 ug/dL and CDC/NIOSH defines adult elevated BLL at >= 3.5-5 ug/dL.

Cholinesterase monitoring for organophosphate/carbamate exposure tracks RBC acetylcholinesterase and plasma cholinesterase, requiring mandatory worker removal when RBC AChE depression reaches >= 30% below pre-exposure baseline.

Pre-analytical urine sample validity requires strict screening: samples with creatinine < 0.3 g/L or > 3.0 g/L, or specific gravity < 1.010 or > 1.030, are physiologically invalid and cannot be interpreted.

Last updated: August 2026

Biological Exposure Indices (BEIs) and Biomonitoring

Biological monitoring ( biomonitoring ) is the systematic evaluation of human exposure to chemical agents through the collection and analysis of biological specimens—principally urine , whole blood , serum , or exhaled breath . While personal air monitoring quantifies external airborne exposure, biological monitoring measures the internal effective biological dose , integrating all exposure pathways (inhalation, dermal penetration, and incidental gastrointestinal ingestion), variations in physical workload/ventilation rate, non-occupational exposures, and individual metabolic phenotypes.

1. Principles of Biological Monitoring and ACGIH BEIs +-------------------------------------------------------------+

  • | AIR MONITORING VS. BIOLOGICAL MONITORING |
  • +-------------------------------------------------------------+
  • | |
  • | PERSONAL AIR SAMPLING BIOLOGICAL MONITORING |
  • | - External airborne concentration - Internal effective dose|
  • | - Inhalation route ONLY - Integrates ALL routes: |
  • | - Assumes standard breathing Inhalation, Dermal, GI |
  • | - Ignores PPE effectiveness - Accounts for PPE bypass |
  • | - Ignores worker metabolism - Captures worker kinetics |
  • +-------------------------------------------------------------+
  • ACGIH Biological Exposure Indices (BEIs)

A Biological Exposure Index (BEI) is a reference value published by ACGIH representing the concentration of a determinant (parent chemical, metabolite, or reversible biochemical change) in a biological specimen collected from a healthy worker who has been exposed to airborne chemicals at the ACGIH TLV-TWA .

BEIs are guidelines , not legal mandates (unless adopted into specific OSHA substance standards).

BEIs do not distinguish between hazardous and non-hazardous exposures in single isolated tests; they indicate whether worker exposure is comparable to that resulting from air concentrations at the TLV.

ACGIH BEI Notations

'B' (Background Baseline): The determinant is present in significant detectable quantities in biological specimens of the general public without occupational exposure (e.g., Acetone in urine from endogenous metabolism; Carbon Monoxide in blood from urban air pollution).

'Nq' (Non-Quantitative): Biological monitoring is recommended, but quantitative data are insufficient to establish a numerical BEI.

'Ns' (Non-Specific): The determinant is non-specific and can arise from other chemical exposures, foods, or common over-the-counter medications (e.g., Hippuric acid in urine from dietary sodium benzoate; t,t-Muconic acid from sorbic acid).

'Sq' (Semi-Quantitative): The biological determinant is a marker of exposure but has high analytical or biological variability.

2. Specimen Collection Chronobiology & Sampling Timing

The timing of biological specimen collection is determined by the elimination half-life (t(1/2)) of the chemical determinant. Sampling at the wrong physiological timeframe produces completely invalid results. +-------------------------------------------------------------+

  • | BEI SPECIMEN COLLECTION CHRONOBIOLOGY |
  • +-------------------------------------------------------------+
  • | |
  • | PRIOR TO SHIFT (16 hr post-exposure) |
  • | - Target: Chemicals with intermediate half-lives |
  • | - Reflects previous days' accumulated exposure |
  • | - Example: Fluorides in urine |
  • | |
  • | END OF SHIFT (Immediately at cessation of work) |
  • | - Target: Rapidly eliminated metabolites (t1/2 < 5 hr) |
  • | - Reflects same-day shift exposure |
  • | - Example: Acetone, MEK, o-Cresol (Toluene), SPMA (Benzene)|
  • | |
  • | END OF WORKWEEK (After 4-5 consecutive days) |
  • | - Target: Moderately persistent chemicals (t1/2 15-40 hr) |
  • | - Reflects cumulative weekly body burden |
  • | - Example: Methylhippuric acids (Xylenes), Mandelic (Styr) |
  • | |
  • | DISCRETIONARY / ANY TIME |
  • | - Target: Highly persistent accumulators (t1/2 > months) |
  • | - Reflects steady-state chronic body burden |
  • | - Example: Lead in blood, Cadmium in urine/blood |
  • +-------------------------------------------------------------+
  • Timing Category Details

Prior to Shift (16 hours post-exposure):

Collected before the worker begins the next work shift, after at least 16 hours without exposure.

Eliminates transient acute spikes, measuring persistent body burden accumulated over previous shifts.

End of Shift (immediately at work cessation):

Collected as soon as possible after the employee finishes the work shift.

Ideal for volatile solvents and rapid Phase I/II metabolites (t(1/2) < 5 hours).

End of Workweek (after 4 to 5 working days):

Collected at the end of the shift on the final day of the workweek (e.g., Friday afternoon).

Measures toxicants that accumulate across work shifts due to biological half-lives of 15 to 40 hours.

Discretionary / Any Time:

Biological determinants with exceedingly long half-lives (t(1/2) > 1 year) achieve stable multi-year steady-state plateaus that do not fluctuate meaningfully across shifts or weeks.

  • 3. Major Occupational Biological Monitoring Systems
  • Comprehensive Summary Table of Critical Industrial BEIs

Chemical Agent Biomarker Determinant Biological Matrix Sampling Time ACGIH BEI Value Primary Notes & Cross-Interferences

Inorganic Lead Lead in whole blood (BLL) Whole Blood Discretionary / Any Time 200 µg/L (20 µg/dL) OSHA Medical Removal at 50 µg/dL (General Industry). CDC/NIOSH adult reference: ≥ 3.5--5 µg/dL.

Inorganic Lead Zinc Protoporphyrin (ZPP) Whole Blood Discretionary / Any Time — Reflects bone marrow heme enzyme inhibition over 120-day RBC lifespan; lags BLL changes by 2-3 months.

Carbon Monoxide Carboxyhemoglobin (COHb) Whole Blood End of shift 3.5% of total Hb Heavy tobacco smokers exhibit non-occupational baselines of 5--10% COHb ('B' notation).

Carbon Monoxide Carbon Monoxide in end-exhaled air End-tidal Alveolar Air End of shift 20 ppm Non-invasive surrogate for venous COHb.

Benzene S-Phenylmercapturic acid (SPMA) Urine End of shift 25 µg/g creatinine Highly specific glutathione metabolite ('B' notation in urban air).

Benzene trans,trans-Muconic acid (t,t-MA) Urine End of shift 500 µg/g creatinine Sensitive, but non-specific ('Ns'): dietary sorbic acid food preservative cross-reacts.

Toluene o-Cresol in urine Urine End of shift 0.3 mg/g creatinine Specific Phase I phenolic metabolite.

Toluene Toluene in blood Whole Blood Prior to last shift of workweek 0.02 mg/L Sensitive parent compound determinant.

Methyl Ethyl Ketone MEK in urine Urine End of shift 2.0 mg/L Unmodified parent solvent excreted in urine.

Xylenes Methylhippuric acids Urine End of shift 1.5 g/g creatinine Sum of ortho-, meta-, and para-isomers.

Styrene Mandelic acid plus Phenylglyoxylic acid Urine End of shift 400 mg/g creatinine Sequential Phase I/II metabolites ('Ns').

Organophosphates Cholinesterase activity in RBC / Plasma Whole Blood (Heparinized) Discretionary (vs. Pre-exposure Baseline) ≥ 70% of Baseline (≤ 30% depression) Mandatory worker removal when RBC acetylcholinesterase depression reaches ≥ 30%.

4. Deep Dives: Lead, Carbon Monoxide, and Cholinesterase

Inorganic Lead Biomonitoring: BLL vs. ZPP & Regulatory Mandates +-------------------------------------------------------------+

  • | LEAD BIOMARKER COMPARISON |
  • +-------------------------------------------------------------+
  • | |
  • | BLOOD LEAD LEVEL (BLL) ZINC PROTOPORPHYRIN (ZPP) |
  • | - Gold standard for RECENT - Gold standard for CHRONIC |
  • | exposure (t1/2 ~ 30 days) exposure (t1/2 ~ 120 days)|
  • | - Direct circulating metal - Indirect heme inhibition |
  • | - Rapidly reflects exposure (Ferrochelatase block) |
  • | changes and controls - Lags BLL shifts by 2-3 mo |
  • +-------------------------------------------------------------+

OSHA Medical Removal Protection (29 CFR 1910.1025 - General Industry):

Removal Criteria: Mandatory removal of an employee from lead work if a single blood lead test reaches ≥ 60 µg/dL , or if the average of the last three blood lead tests (or all tests over the previous 6 months) reaches ≥ 50 µg/dL .

Return to Work Criteria: Worker may return to former lead work duties only after two consecutive blood lead tests indicate BLL < 40 µg/dL .

Medical Removal Protection Benefits (MRPB): Employer must maintain total earnings, seniority, and employment rights for up to 18 months during removal.

OSHA Construction Standard (29 CFR 1926.62): Mandatory removal at ≥ 50 µg/dL ; return at < 40 µg/dL .

Zinc Protoporphyrin (ZPP): Lead inhibits the mitochondrial enzyme ferrochelatase , which inserts ferrous iron (Fe²⁺) into protoporphyrin IX. Zinc substitutes for iron, producing ZPP. Because ZPP is incorporated into erythrocytes during erythropoiesis, it reflects average exposure over the red cell lifespan (120 days) and lags blood lead changes by 8 to 12 weeks.

Carbon Monoxide Biomonitoring: Coburn-Foster-Kane (CFK) Modeling

Carboxyhemoglobin (% COHb) in blood is evaluated at the end of the shift against the BEI of 3.5% .

The mathematical accumulation and clearance of COHb are modeled by the Coburn-Foster-Kane (CFK) equation , which accounts for:

  • Ambient airborne CO concentration (PCO)
  • Alveolar ventilation rate (VA, determined by physical workload)
  • Endogenous CO production rate (VCO)
  • Blood volume and total hemoglobin mass
  • Barometric pressure and ambient oxygen partial pressure (P(O2))
  • Pulmonary capillary diffusion capacity (DL)

In non-smokers, breathing air at the ACGIH TLV (25 ppm) for 8 hours produces an equilibrium COHb of approximately 3.5% .

Cholinesterase Inhibition: Organophosphates and Carbamates

Organophosphate (OP) and carbamate insecticides inhibit serine esterase enzymes, specifically Acetylcholinesterase (AChE) at neuromuscular junctions and autonomic synapses, causing life-threatening accumulation of acetylcholine (cholinergic toxidrome: SLUDGE — Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis). +-------------------------------------------------------------+

  • | RBC AChE VS. PLASMA PSEUDOCHOLINESTERASE |
  • +-------------------------------------------------------------+
  • | |
  • | RBC ACETYLCHOLINESTERASE (AChE) PLASMA CHOLINESTERASE (BChE)|
  • | - True acetylcholinesterase - Pseudocholinesterase |
  • | - Located on erythrocyte membrane - Synthesized by liver |
  • | - Exact proxy for neural synapse - Highly sensitive, rapid |
  • | - Slow recovery (~1% per day) - Fast recovery (weeks) |
  • | - PRIMARY REGULATORY METRIC - Screening biomarker |
  • +-------------------------------------------------------------+

Clinical Action Thresholds:

Pre-Exposure Baseline: Must be established before chemical handling begins (average of at least 2 tests taken 3 to 14 days apart).

Exposure Investigation / Re-test: Triggered when RBC AChE or plasma BChE drops ≥ 20% below baseline .

Mandatory Medical Removal: Mandatory removal of the worker from pesticide application duties when RBC AChE depression reaches ≥ 30% below baseline (or plasma BChE drops ≥ 40--50% below baseline in state-mandated programs such as California Cal/OSHA).

Return to Work: Worker may resume pesticide duties when RBC AChE recovers to ≥ 80% of baseline .

5. Pre-Analytical Specimen Quality & Normalization

Because hydration status alters urinary dilution, raw spot urine contaminant concentrations (extmg/L or µg/L) can be wildly misleading. ACGIH and clinical toxicology laboratories apply strict pre-analytical validity criteria.

ACGIH Specimen Validity Screening Limits

A spot urine specimen is considered physiologically invalid for BEI determination if:

Creatinine Concentration: < 0.3 g/L (30 mg/dL, too dilute) OR > 3.0 g/L (300 mg/dL, too concentrated).

Specific Gravity (SG): < 1.010 (too dilute) OR > 1.030 (too concentrated).

Exam Rule: If a urine sample fails these criteria, the laboratory result cannot be interpreted . Another urine specimen must be collected after normal fluid intake is established. +-------------------------------------------------------------+

  • | URINE SPECIMEN VALIDITY WINDOWS |
  • +-------------------------------------------------------------+
  • | Creatinine: |
  • | [ Invalid: < 0.3 g/L ] | ACCEPTABLE: 0.3 to 3.0 g/L | [ Invalid: > 3.0 g/L ]
  • | |
  • | Specific Gravity: |
  • | [ Invalid: < 1.010 ] | ACCEPTABLE: 1.010 to 1.030 | [ Invalid: > 1.030 ]
  • +-------------------------------------------------------------+
  • Mathematical Adjustment Formulas
  • 1. Creatinine Normalization

Used for organic metabolites (expressed in µg/g creatinine or mg/g creatinine): C adj ( μ g/g creatinine ) = C measured ( μ g/L ) Urinary Creatinine ( g/L ) \mathbf{C_{\text{adj}}\,(\mu\text{g/g creatinine}) = \frac{C_{\text{measured}}\,(\mu\text{g/L})}{\text{Urinary Creatinine}\,(\text{g/L})}} C adj ​ ( μ g/g creatinine ) = Urinary Creatinine ( g/L ) C measured ​ ( μ g/L ) ​

2. Specific Gravity Normalization

Used for inorganic metals and electrolytes when creatinine correction is inappropriate, normalizing to standard reference urine specific gravity of 1.024 : C adj = C measured × ( 1.024 − 1.000 SG sample − 1.000 ) = C measured × ( 0.024 SG sample − 1.000 ) \mathbf{C_{\text{adj}} = C_{\text{measured}} \times \left(\frac{1.024 - 1.000}{\text{SG}_{\text{sample}} - 1.000}\right) = C_{\text{measured}} \times \left(\frac{0.024}{\text{SG}_{\text{sample}} - 1.000}\right)} C adj ​ = C measured ​ × ( SG sample ​ − 1.000 1.024 − 1.000 ​ ) = C measured ​ × ( SG sample ​ − 1.000 0.024 ​ )

  • 6. Worked Step-by-Step Practical Biomonitoring Examples
  • Worked Example 5.4.1: Urinary Biomarker Specific Gravity Correction

Problem: A boat manufacturing worker laminating fiberglass hulls is monitored for styrene exposure. A spot urine sample collected at the end of the shift contains a measured combined Mandelic acid + Phenylglyoxylic acid concentration (Cmeasured) of 320 mg/L. Refractometer analysis reveals a urine specific gravity (extSG) of 1.012.

Check if the urine specimen meets ACGIH validity criteria.

Calculate the specific gravity-adjusted biomarker concentration (Cadj) normalized to reference SG = 1.024.

Compare the adjusted result to the ACGIH BEI of 400 mg/g creatinine (equivalent to 400 mg/L at standard density).

Solution Steps:

Verify specimen validity:

SG = 1.012 falls between 1.010 and 1.030 → Valid Specimen.

Apply Specific Gravity Adjustment Formula: C adj = C measured × ( 1.024 − 1.000 SG sample − 1.000 ) C_{\text{adj}} = C_{\text{measured}} \times \left(\frac{1.024 - 1.000}{\text{SG}_{\text{sample}} - 1.000}\right) C adj ​ = C measured ​ × ( SG sample ​ − 1.000 1.024 − 1.000 ​ ) C adj = 320 mg/L × ( 0.024 1.012 − 1.000 ) = 320 × ( 0.024 0.012 ) = 320 × 2.00 = 640 mg/L C_{\text{adj}} = 320\,\text{mg/L} \times \left(\frac{0.024}{1.012 - 1.000}\right) = 320 \times \left(\frac{0.024}{0.012}\right) = 320 \times 2.00 = 640\,\text{mg/L} C adj ​ = 320 mg/L × ( 1.012 − 1.000 0.024 ​ ) = 320 × ( 0.012 0.024 ​ ) = 320 × 2.00 = 640 mg/L

Evaluation:

Raw uncorrected result (320 mg/L) appeared to comply with the 400 mg/L benchmark.

However, because the sample was highly dilute (extSG = 1.012), the standardized concentration is 640 mg/L , revealing a significant biological overexposure exceeding the BEI.

Result: The adjusted concentration is 640 mg/L , demonstrating that dilution correction is essential to avoid false-negative exposure assessments.

Worked Example 5.4.2: Creatinine Correction and Specimen Validity Assessment

Problem: End-of-shift urine samples are collected from two chemical operators exposed to benzene vapor (BEI for S-Phenylmercapturic acid [SPMA] = 25.0 µg/g creatinine):

Operator 1: Measured SPMA = 18.0 µg/L; Measured Creatinine = 1.20 g/L.

Operator 2: Measured SPMA = 6.0 µg/L; Measured Creatinine = 0.15 g/L.

Assess the analytical validity of each specimen under ACGIH rules.

For valid specimens, calculate the normalized SPMA concentration in µg/g creatinine and evaluate compliance.

Solution Steps:

Validity Screening:

Operator 1: Creatinine = 1.20 g/L (0.30 ≤ 1.20 ≤ 3.0 g/L) → Valid Specimen.

Operator 2: Creatinine = 0.15 g/L (0.15 < 0.30 g/L, excessively dilute) → INVALID Specimen. Must reject and re-sample.

Calculate Creatinine-Normalized Concentration for Operator 1: SPMA norm = C SPMA Creatinine = 18.0 μ g/L 1.20 g/L = 15.0 μ g/g creatinine \text{SPMA}_{\text{norm}} = \frac{C_{\text{SPMA}}}{\text{Creatinine}} = \frac{18.0\,\mu\text{g/L}}{1.20\,\text{g/L}} = 15.0\,\mu\text{g/g creatinine} SPMA norm ​ = Creatinine C SPMA ​ ​ = 1.20 g/L 18.0 μ g/L ​ = 15.0 μ g/g creatinine

Compliance Evaluation:

Operator 1: 15.0 µg/g creatinine ≤ 25.0 µg/g creatinine → Within BEI.

Result: Operator 1's specimen is valid and compliant at 15.0 µg/g creatinine ; Operator 2's sample is invalid due to excessive dilution (0.15 g/L creatinine) and must be recollected.

Worked Example 5.4.3: Cholinesterase Depression Calculation & Medical Removal Determination

Problem: An agricultural worker applying chlorpyrifos (organophosphate) has pre-exposure baseline cholinesterase tests established prior to spray season:

  • Baseline Test 1: RBC AChE = 12.8 IU/g Hb
  • Baseline Test 2: RBC AChE = 12.2 IU/g Hb

During mid-season biomonitoring, the worker's RBC AChE is measured at 8.5 IU/g Hb.

Calculate the worker's average baseline RBC AChE activity.

Calculate the percentage depression of RBC AChE activity from baseline.

Determine the required industrial hygiene and medical action.

Solution Steps:

Calculate average pre-exposure baseline: Baseline = 12.8 + 12.2 2 = 12.5 IU/g Hb \text{Baseline} = \frac{12.8 + 12.2}{2} = 12.5\,\text{IU/g Hb} Baseline = 2 12.8 + 12.2 ​ = 12.5 IU/g Hb

Calculate percentage depression: % Depression = ( Baseline − Measured Baseline ) × 100 % \%\,\text{Depression} = \left(\frac{\text{Baseline} - \text{Measured}}{\text{Baseline}}\right) \times 100\% % Depression = ( Baseline Baseline − Measured ​ ) × 100% % Depression = ( 12.5 − 8.5 12.5 ) × 100 % = ( 4.0 12.5 ) × 100 % = 32.0 % \%\,\text{Depression} = \left(\frac{12.5 - 8.5}{12.5}\right) \times 100\% = \left(\frac{4.0}{12.5}\right) \times 100\% = 32.0\% % Depression = ( 12.5 12.5 − 8.5 ​ ) × 100% = ( 12.5 4.0 ​ ) × 100% = 32.0%

Regulatory and Medical Determination:

An enzyme depression of 32.0% exceeds the 30% medical removal threshold .

Action Required: The worker must be immediately removed from all pesticide handling and application duties .

The worker may return to pesticide work only after follow-up testing demonstrates that RBC AChE activity has recovered to ≥ 80% of baseline (12.5 × 0.80 = 10.0 IU/g Hb).

Result: The worker exhibits a 32.0% RBC AChE depression , requiring mandatory medical removal until enzyme levels recover to at least 10.0 IU/g Hb .